Cardiac glycosides and the risk of breast cancer in women with chronic heart failure and supraventricular arrhythmia.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Couraud S;Couraud S; Dell'Aniello S; Bouganim N; Azoulay L
  • Source:
    Breast cancer research and treatment [Breast Cancer Res Treat] 2014 Aug; Vol. 146 (3), pp. 619-26. Date of Electronic Publication: 2014 Jul 20.
  • Publication Type:
    Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
    • Publication Information:
      Publication: Dordrecht : Kluwer Academic
      Original Publication: The Hague ; Boston : M. Nijhoff, c1981-
    • Subject Terms:
      Arrhythmias, Cardiac/*epidemiology ; Breast Neoplasms/*epidemiology ; Cardiac Glycosides/*administration & dosage ; Heart Failure/*epidemiology; Adult ; Aged ; Arrhythmias, Cardiac/complications ; Arrhythmias, Cardiac/pathology ; Breast Neoplasms/chemically induced ; Breast Neoplasms/etiology ; Case-Control Studies ; Female ; Heart Failure/complications ; Heart Failure/pathology ; Heart Ventricles/drug effects ; Heart Ventricles/pathology ; Humans ; Middle Aged ; Risk Factors ; United Kingdom
    • Abstract:
      The aim of this study is to determine whether the use of cardiac glycosides (CGs), drugs used in the treatment of congestive heart failure (CHF) and supra-ventricular arrhythmia, is associated with an increased risk of breast cancer. A cohort of 53,454 women newly diagnosed with CHF or supra-ventricular arrhythmia between January 1, 1988 and December 31, 2010, followed until December 31, 2012, was identified using the United Kingdom Clinical Practice Research Datalink. A nested case-control analysis was performed, where all incident cases of breast cancer occurring during follow-up were identified and matched with up to 10 controls on age, cohort entry date, and duration of follow-up. Conditional logistic regression models were used to estimate adjusted odds ratios (ORs) with 95 % confidence intervals (CIs) of incident breast cancer associated with the use of CGs, along with measures of cumulative duration of use and dose. All analyses considered a one year lag period prior to the event, necessary for latency considerations and to minimize detection bias. The 898 breast cancer cases diagnosed beyond one year of follow-up were matched to 8,940 controls. Overall, use of CGs was not associated with an increased risk of breast cancer when compared to non-use (OR 1.07, 95 % CI 0.90-1.26). Furthermore, the risk did not vary with cumulative duration of use or cumulative dose. The findings of this large population-based study indicate that the use of CGs is not associated with an increased risk of breast cancer. This should provide reassurance to physicians and patients using these drugs.
    • Grant Information:
      Canada Canadian Institutes of Health Research
    • Accession Number:
      0 (Cardiac Glycosides)
    • Publication Date:
      Date Created: 20140721 Date Completed: 20150330 Latest Revision: 20161125
    • Publication Date:
      20240829
    • Accession Number:
      10.1007/s10549-014-3058-8
    • Accession Number:
      25038879